WHO Pharmaceuticals Newsletter 2004, No. 04
(2004; 14 pages) View the PDF document
Table of Contents
Close this folderREGULATORY MATTERS
View the documentALOSETRON - Risk management plan to remain in place
View the documentANTIDEPRESSANTS - Health Canadaendorsed safety information
View the documentBUPROPION - Labelling updated to include class warning
View the documentCLOZAPINE - Labelling to include updated patient safety registry information
View the documentDEXTROPROPOXYPHENE/PARACETAMOL - Prescribing reminder
View the documentDOMPERIDONE - Not to be used to increase milk production in women
View the documentLEFLUNOMIDE - Update on interstitial lung disease
View the documentROSUVASTATIN - Higher dose and predisposing factors linked with rhabdomyolysis
View the documentSULPHUR HEXAFLUORIDE - Use in echocardiography suspended
Open this folder and view contentsSAFETY OF MEDICINES
View the documentANNOUNCEMENT
 

DOMPERIDONE - Not to be used to increase milk production in women

USA. The Food and Drug Administration (FDA) is warning breastfeeding women not to use domperidone to augment lactation because of safety concerns. The agency is concerned with the potential public health risks associated with domperidone.

Domperidone is not approved in the US for any indication. Some women who breastfeed and/or pump breast milk are purchasing this drug from compounding pharmacies in the US and from sources in foreign countries. The FDA has issued warning letters to the pharmacies that compound domperidone containing products and to firms that supply domperidone to pharmacies in the US. Although domperidone is approved in several countries outside the US to treat certain gastric disorders, it is not approved in any country for enhancing breast milk production in lactating women. Worldwide there have been several published reports and case studies of cardiac arrhythmias, cardiac arrest and sudden death in patients receiving an intravenous form of domperidone that has been withdrawn from the market in a number of countries. In several countries where the oral form is still marketed, labels for the product contain specific warnings against use of domperidone by breastfeeding women and note that the drug is excreted in breast milk that could expose a breastfeeding infant to unknown risks.

Reference:

FDA Talk Paper, 7 June 2004. Available on the Internet at www.fda.gov

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 6, 2017